source
- Replimune’s Tudriqev immunotherapy receives FDA accelerated approval for advanced melanomaReplimune announced that the FDA granted accelerated approval for its immunotherapy, now branded Tudriqev, in combination with Bristol Myers Squibb’s Opdivo. The decision follows two earlier reject…
- FDA approves first mRNA seasonal flu vaccine, mFlusiva, a year after funding cutsThe U.S. Food and Drug Administration granted approval to mFlusiva, the first mRNA‑based seasonal influenza vaccine, after its advisory committee voted unanimously that the benefits outweigh the ri…